Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. [electronic resource]
Producer: 20141002Description: S307-9 p. digitalISSN:- 2152-2669
- Animals
- Humans
- Janus Kinase 2 -- antagonists & inhibitors
- Molecular Targeted Therapy
- Myeloproliferative Disorders -- drug therapy
- Phosphatidylinositol 3-Kinases -- metabolism
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-akt -- metabolism
- Signal Transduction -- drug effects
- TOR Serine-Threonine Kinases -- metabolism
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.